In this guide10 sections
- Breast Implant-Associated Anaplastic Large Cell Lymphoma: Understanding the Risks and Symptoms of this Rare Cancer
- BIA-ALCL: Understanding this Rare Type of Cancer Associated with Breast Implants
- How Common Is BIA-ALCL? What the Research Actually Shows
- The 2019 Allergan Biocell Recall
- Understanding the Risk Factors for BIA-ALCL
- Recognising the Symptoms and Signs of BIA-ALCL: What to Watch For
- Methods for Diagnosing BIA-ALCL
- Effective Treatment Options for BIA-ALCL
- Frequently Asked Questions About BIA-ALCL
- Breast Surgery at Centre for Surgery
Breast Implant-Associated Anaplastic Large Cell Lymphoma: Understanding the Risks and Symptoms of this Rare Cancer
For decades, breast implants have been a popular cosmetic procedure among women who wish to enhance the appearance of their breasts. While breast implants are generally regarded as safe, a rare but serious cancer has been identified in association with textured implants: Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), also referred to as breast implant lymphoma or breast implant-associated cancer. This is not a new discovery — the first case was documented in 1997, the US Food and Drug Administration issued its first safety communication in 2011, and the evidence base has been building steadily ever since.
Unlike Breast Implant Illness (BII), which is a collection of symptoms reported by some women with breast implants, BIA-ALCL is a defined malignancy affecting a small number of women with textured implants. It is also distinct from capsular contracture, a benign hardening of the scar capsule and by far the more common complication, and from implant rupture. These conditions are frequently confused with one another and carry very different levels of concern.
It is crucial to be aware of the symptoms and signs associated with BIA-ALCL, so that prompt diagnosis and treatment can be sought. Symptoms of BIA-ALCL can include breast swelling, pain, lumps, or asymmetry, as well as fever and night sweats.
The good news is that early diagnosis and swift surgical treatment of BIA-ALCL can result in very positive outcomes. Treatment typically involves the removal of the implants and surrounding capsule en-bloc, which has been shown to provide excellent outcomes, with many patients making a full recovery. A systematic review of 178 reported cases found that en bloc capsulectomy was performed in 96.8% of cases where treatment details were available, and that recurrence and mortality were strongly concentrated in patients presenting with advanced disease rather than localised disease (DOI ↗). That finding is the single strongest argument for not ignoring a late seroma.
READ THE LATEST UK GOVERNMENT GUIDANCE ON BIA-ALCL HERE ↗
BIA-ALCL: Understanding this Rare Type of Cancer Associated with Breast Implants
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare type of cancer that can develop in women with certain types of breast implants. Unlike breast cancer, which develops in the breast tissue, BIA-ALCL arises from immune cells in the breast, and is therefore classified as a type of T-cell lymphoma. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) monitors BIA-ALCL cases and safety data for implants used in the UK, alongside international regulators.
BIA-ALCL is typically detected when cancer cells are found in the fluid (effusion) that accumulates around the implant, or in the surrounding scar tissue (capsule).
How Common Is BIA-ALCL? What the Research Actually Shows
This is the question most people want answered first, and the honest answer is that the reported figures vary widely depending on which population is studied and how carefully implants are tracked.
A global epidemiological review in Plastic and Reconstructive Surgery found that risk estimates have risen from early figures of around 1 in a million to a current estimate of roughly 1 in 2,832 for high-textured, high-surface-area implants — the highest-risk category. The authors were explicit that this rise reflects better awareness, better reporting and more precise analysis of specific implant subtypes, rather than the disease itself becoming more dangerous (DOI ↗).
A separate single-institution study at Memorial Sloan Kettering, which tracked 9,373 reconstruction patients and 16,065 implants over 26 years, reported an incidence of 1 in 559 patients with textured implants, with a median time to diagnosis of 10.3 years. Every one of the eleven cases identified had a history of textured implants (DOI ↗).
Two points matter when reading these numbers. First, they apply to patients who have had textured implants — the risk with smooth implants is very much lower, and no case has been convincingly linked to a patient who has only ever had smooth devices. Second, the wide range between studies reflects genuine difficulty in counting both cases and the total number of women with implants, not disagreement about whether the condition is rare. It is rare.
The 2019 Allergan Biocell Recall
In July 2019, following a request from the FDA, Allergan issued a worldwide recall of its Biocell textured breast implants and tissue expanders after data showed these devices accounted for a disproportionate share of reported BIA-ALCL cases. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) confirmed the recall applied in the UK.
Guidance from regulators has been consistent since: routine removal of textured implants is not recommended for women who have no symptoms. The reasoning is straightforward — the risk of the lymphoma is low, whereas surgery to remove implants carries its own certain risks of anaesthetic, bleeding, infection and scarring. Removal is recommended where symptoms develop.
If you do not know what implants you have, your operating surgeon or the hospital where you had surgery should hold your implant record card, which lists manufacturer, model and lot number. A breast implant check can also establish what is in place.
Understanding the Risk Factors for BIA-ALCL
BIA-ALCL is a relatively recent medical discovery, and as a result, doctors are still working to understand its underlying causes. The British Association of Aesthetic Plastic Surgeons (BAAPS) ↗ has identified several factors that may contribute to an increased risk of developing breast implant-associated cancer:
- The Connection between Textured Implants and BIA-ALCL: Among the known risk factors, textured implants stand out as the most prominent. A majority of reported BIA-ALCL cases involve women with textured breast implants, particularly those manufactured by Allergan.
- The Role of Bacterial Contamination in BIA-ALCL: During surgical procedures, breast implants may occasionally become contaminated with harmful bacteria. This contamination can lead to inflammation, which is believed to elevate the risk of developing BIA-ALCL.
- The Impact of Time Since Surgery on BIA-ALCL Occurrence: BIA-ALCL typically manifests within 7 to 10 years following implantation. A systematic review in JAMA Surgery covering every case reported between 1997 and 2017 found a mean time to presentation of approximately 10 years, with 66% of patients first seen with an isolated late-onset seroma and 8% with an isolated new breast mass (DOI ↗). This is why a swelling that appears years after surgery is treated seriously, while swelling in the first weeks is expected and usually means something else entirely.
- The Potential Involvement of Genetic Predisposition in BIA-ALCL: Researchers have also identified possible links between genetic predisposition and BIA-ALCL. Specifically, mutations in the JAK1 and STAT3 genes may play a role.
Recognising the Symptoms and Signs of BIA-ALCL: What to Watch For
Awareness of the symptoms associated with BIA-ALCL is crucial for early detection and prompt intervention.
- Asymmetry Between Breasts – If you notice a sudden or significant difference in the appearance of your breasts, this asymmetry could be a warning sign of BIA-ALCL.
- Swelling or Lumps in the Armpit Area – Swollen or enlarged lymph nodes in the armpit area may also signal the presence of BIA-ALCL.
- Swelling in the Breast – One of the primary indicators of BIA-ALCL is breast swelling, which may develop gradually or suddenly.
- Fluid Buildup and Seroma Formation – Fluid accumulation beneath the skin, known as seroma, can be another symptom of BIA-ALCL.
- Changes in Breast Shape or Size – Any alterations in the shape or size of your breast should be discussed with your surgeon.
- Experiencing Breast Pain – A painful breast can be a warning sign of BIA-ALCL and should not be ignored.
- Detecting Breast Lumps – If you feel a lump in your breast, it is essential to consult your plastic surgeon.
- Redness and Inflammation – Unexplained redness or inflammation around the breast area may also indicate the presence of BIA-ALCL.
Prioritising Early Detection and Consultation
It is crucial not to delay seeking medical attention if you experience any of these symptoms. An early diagnosis of breast implant-associated lymphoma can greatly improve the chances of successful treatment and recovery.
Methods for Diagnosing BIA-ALCL
Plastic surgeons use various methods to diagnose BIA-ALCL, including:
- Patient Examination – Your plastic surgeon will conduct a physical examination of your breasts and armpits, asking you about any symptoms you may have noticed.
- Ultrasound Imaging – A non-invasive, safe technique that uses sound waves to create an image of the breast tissue. It can detect any fluid, masses, or lymph nodes near your implants.
- Magnetic Resonance Imaging (MRI) – An advanced imaging technique that can detect any tissue abnormalities in your breasts, including BIA-ALCL.
- Needle Biopsy – If ultrasound or MRI scanning reveals something suspicious near your breast implant, your surgeon may perform a needle biopsy.
CD30 Testing – CD30 is a protein receptor found on activated T-cell lymphocytes. A positive CD30 test result is an indication of possible BIA-ALCL, and further testing will be needed to confirm the diagnosis. BIA-ALCL cells are characteristically CD30 positive and ALK negative, which is what distinguishes this lymphoma from other subtypes.
The American Association of Plastic Surgeons published a multidisciplinary consensus statement in 2024, drawing on 145 studies, setting out current recommendations on diagnosis, surveillance and management, and stressing that surgeons should be aware of how sharply risk varies by implant surface type (DOI ↗).
Effective Treatment Options for BIA-ALCL
BIA-ALCL is a rare type of cancer that can develop after receiving breast implants. Fortunately, there are several treatment options available that have shown to be effective.
Testing and Staging
Before starting treatment for BIA-ALCL, it is important to undergo proper testing and staging by an oncologist.
Surgical Treatment
Surgery has been the most effective and commonly used treatment for BIA-ALCL. An experienced breast surgeon can perform En-bloc or complete capsulectomy excision to remove the old implant and surrounding fibrous tissue capsule. This surgery has been shown to be highly effective in treating BIA-ALCL.
Additional Treatment Options
In rare cases where surgery alone is not enough, other treatment options may be recommended. Chemotherapy may be used to destroy cancer cells with medication. Radiotherapy is also an option that may be used in addition to surgery.
Reconstruction Options
After the treatment of BIA-ALCL, breast reconstruction using new implants or a breast lift can be done in most cases.
Frequently Asked Questions About BIA-ALCL
Is BIA-ALCL common?
No — it’s a rare condition. The vast majority of women with breast implants, including textured implants, never develop it. Being aware of the symptoms is a sensible precaution, not a reason for alarm.
Does having smooth implants mean I can’t get BIA-ALCL?
No confirmed cases have been reported in the medical literature involving only smooth implants, which is one of the reasons most UK surgeons — including our own team — have moved away from heavily textured implants. See our guide on textured vs smooth breast implants for the full picture.
How long after breast implants can BIA-ALCL develop?
It typically manifests within 7 to 10 years following implantation, though ongoing monitoring is advisable for the full lifetime of your implants.
What is the survival rate for BIA-ALCL?
Outcomes are generally very good where the disease is caught while confined to the capsule and treated with complete surgical removal. The systematic review of 178 cases recorded 10 recurrences and 8 deaths attributable to BIA-ALCL, with both strongly associated with advanced presentation — 29% of patients with advanced disease versus 2.1% of those with localised disease (DOI ↗). Stage at diagnosis is the factor that matters most, which is why prompt assessment of a late seroma is emphasised so heavily.
What is a late seroma, and why does it matter?
A seroma is a collection of fluid around the implant. In the first weeks after surgery this is common and expected. A late seroma — fluid appearing more than a year after surgery, and often many years later — is the presenting sign in around two-thirds of BIA-ALCL cases. It is still far more likely to have a benign cause, but it should always be investigated with ultrasound and, if fluid is present, aspiration with the sample sent for CD30 testing and cytology. Aspiration and testing is a straightforward outpatient procedure.
Are smooth or microtextured implants used at Centre for Surgery?
Yes. We use smooth and microtextured implants as standard. Our review of Centre for Surgery outcomes between 2016 and 2022 found no statistically significant difference in capsular contracture rates between smooth and textured devices, which removed the main historical argument for using heavily textured implants at all.
Should I have my textured implants removed as a precaution?
Generally, no, if you have no symptoms — accepted medical guidance is that the risks of an additional surgical procedure usually outweigh the very low risk of BIA-ALCL developing. This is a decision to make with your surgeon based on your specific history.
Breast Surgery at Centre for Surgery
Centre for Surgery is a specialist cosmetic surgery clinic in London, UK, with a team of highly skilled and experienced surgeons specialising in a wide range of cosmetic and reconstructive surgeries. Among our areas of expertise is breast surgery, including breast augmentation, breast reduction, breast lift, and breast implant removal — all performed by GMC-registered plastic surgeons, at our CQC-regulated Baker Street facility, under TIVA (Total Intravenous Anaesthesia) as a day case.
At Centre for Surgery, we understand that every patient is unique and has different needs and goals. That’s why we take a personalised approach to each case, providing our patients with comprehensive consultations to determine the most suitable surgical plan for them.
Our team of surgeons is highly respected in the field of breast surgery and is committed to ongoing education and training to ensure that they are up-to-date with the latest developments in the field.
If you are considering breast surgery, we encourage you to schedule a consultation with one of our experts at Centre for Surgery to discuss your options and determine the best course of action for you.
